

Supplementary Information

Supplementary Table S1. Evaluation of differences in cytokines according to disease severity and phenotype using Pearson correlation analysis.


		Hematocrit	Albumin	ESR	CRP	Calprotectin	PCDAI score	SES-CD score
TNF- α , pg/mL	Pearson coefficient	-0.197	-0.135	0.028	0.231	0.017	0.183	0.286
	P value	0.297	0.476	0.881	0.219	0.928	0.333	0.125
Interleukin 6, pg/mL	Pearson coefficient	-0.210	-0.026	0.033	0.019	0.019	0.099	0.388
	P value	0.265	0.891	0.861	0.548	0.922	0.604	0.034
Interleukin 10, pg/mL	Pearson coefficient	0.119	-0.048	0.004	0.167	0.063	0.100	-0.285
	P value	0.530	0.801	0.982	0.379	0.739	0.601	0.128
Interleukin 17A, pg/mL	Pearson coefficient	0.124	-0.081	0.015	0.161	0.046	0.252	0.217
	P value	0.513	0.670	0.395	0.394	0.809	0.180	0.250


TNF; Tumor necrosis factor, PCDAI; Pediatric Crohn's disease activity index, SDS-CD; Simple endoscopic score for Crohn's disease.

Supplementary Table S2. Comparison of initial cytokine profiles in patients treated with an anti-TNF- α who achieved endoscopic remission versus those who did not achieve endoscopic remission.


	Infliximab use + ER (N = 18)		Infliximab use + No ER (N = 8)		P value
	Mean	SD	Mean	SD	
TNF- α , pg/mL	16.2	12.0	21.8	14.1	0.405 ^a
Interleukin 6, pg/mL	25.1	26.6	25.7	17.5	0.944 ^a
Interleukin 10, pg/mL	110.8	76.0	137.2	134.2	0.636 ^a
Interleukin 17A, pg/mL	9.3	6.8	11.5	9.6	0.592 ^a

ER; Endoscopic remission, SD; Standard deviation, TNF; Tumor necrosis factor.






(c)



(d)



Supplementary Figure S1. Comparison of the (a) TNF- α , (b) Interleukin 6, (c) Interleukin 10, and (d) Interleukin 17A concentrations of patients with and without clinical and biochemical remission, and patients with and without endoscopic remission in patients receiving anti-TNF alpha treatment.